Age, Biography and Wiki

Seth Lederman was born on 30 July, 1957 in New York, New York, United States. Discover Seth Lederman's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is He in this year and how He spends money? Also learn how He earned most of networth at the age of 66 years old?

We recommend you to check the complete list of Famous People born on 30 July. He is a member of famous with the age 66 years old group.

Seth Lederman Height, Weight & Measurements

At 66 years old, Seth Lederman height not available right now. We will update Seth Lederman's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Dating & Relationship status

He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.

Seth Lederman Net Worth

His net worth has been growing significantly in 2022-2023. So, how much is Seth Lederman worth at the age of 66 years old? Seth Lederman’s income source is mostly from being a successful . He is from United States. We have estimated Seth Lederman's net worth , money, salary, income, and assets.

Seth Lederman Social Network

Timeline

As Assistant Professor at Columbia, Dr. Lederman discovered the CD40-Ligand (CD154) and elucidated the molecular basis of T cell helper function. Lederman also collaborated with Professor David Baltimore in identifying and functionally characterizing the CD40 signaling molecule, TRAF-3. Dr. Lederman’s “early work on HIV contributed to the understanding of how the V3 loop of HIV gp120 was involved in fusion with CD4 cell membranes, an early and essential event in viral entry and infection”.

Lederman earned his bachelor's degree in Chemistry from Princeton University where he graduated cum laude in 1979. He completed his M.D. from Columbia University in 1983 and continued his training at the Columbia Presbyterian Medical Center until 1986. Lederman became instructor at Columbia in 1985, Assistant Professor in 1988 and Associate Professor with tenure in 1996. From October 30, 2015 until November 1, 2016 he took a leave of absence and left Columbia in April 2017. In addition to his research, he served as attending physician in the Edward Daniels Faulkner Arthritis Clinic at Columbia Presbyterian Hospital from 1988-1996 and served as Associate Attending physician at Columbia Presbyterian Hospital until 2000 (now New York Presbyterian Hospital).

In September 2015, Lederman represented U.S. Biotechnology at a Summit with China's President Xi Jinping. The Summit was organized by the United States Chamber of Commerce and was held September 17–18, 2015 in Beijing. The delegation of U.S. CEOs, former U.S. cabinet officials and leading academic experts was the 7th meeting of the U.S.-China CEO and Former Senior Officials' Dialogue. The Dialogue was co-chaired by the United States Chamber of Commerce and the China Center for International Economic Exchanges (CCIEE), led by former Vice Premier Zeng Peiyan.

Lederman founded Targent Pharmaceuticals, which sold levoleucovorin to Spectrum Pharmaceuticals, which markets it as Fusilev. Lederman co-founded and served as a managing partner of Konanda Pharma Partners and Konanda Pharma Fund I, LP, and its wholly owned operating companies, Validus and Fontus Pharmaceuticals Inc. Validus acquired Fontus and markets Equetro (carbamazepine – Extended Release), Marplan (isocarboxazid) and Rocaltrol (calcitriol).

Seth Lederman (born July 30, 1957) is a physician, scientist and specialty pharmaceuticals entrepreneur. He is a co-founder and the current President and Chairman of Tonix Pharmaceuticals, a specialty pharmaceutical product development and commercialization company.

TNX-801 is a new potential vaccine for smallpox. TNX-801 is a synthetic form of horsepox, which is an otherwise extinct virus. Evolutionary analysis of modern vaccines indicates that the vaccine isolated and used by Edward Jenner to vaccinate against smallpox was either horsepox or something quite similar. A 1902 sample of vaccinia smallpox vaccine was characterized and found to be 99.7% similar to horsepox, further supporting the connection with Jenner's vaccine. The synthesis of horsepox was a collaboration with David Evans and Ryan Noyce at the University of Alberta in Edmonton, Alberta, Canada. TNX-801 or horsepox is the first poxvirus, or poxviridae, to be synthesized and provides a platform for developing new vaccines against infectious disease and cancer. The finding that a horsepox vaccine was in clinical use in the U.S. in 1902 to protect against smallpox provides strong support for the efficacy of TNX-801 horsepox vaccine to protect against smallpox.